Literature DB >> 33313656

Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections.

Nathaniel C Warner1, Luther A Bartelt1, Anne M Lachiewicz1, Kathleen M Tompkins1, Melissa B Miller2,3, Kevin Alby2,3, Melissa B Jones2, Amy L Carr4, Jose Alexander5, Andrew B Gainey6, Robert Daniels6, Anna-Kathryn Burch6,7, David E Brown6,7, Michael J Brownstein8, Faiqa Cheema9, Kristin E Linder10, Ryan K Shields11,12, Sarah Longworth13, David van Duin1.   

Abstract

Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Achromobacter xylosoxidans; cefiderocol; cystic fibrosis; lung transplantation; pneumonia

Mesh：

Substances：

Year:  2021        PMID： 33313656      PMCID： PMC8678443          DOI： 10.1093/cid/ciaa1847

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  14 in total

1.  Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

Authors:  Simon Portsmouth; David van Veenhuyzen; Roger Echols; Mitsuaki Machida; Juan Camilo Arjona Ferreira; Mari Ariyasu; Peter Tenke; Tsutae Den Nagata
Journal:  Lancet Infect Dis       Date:  2018-10-25       Impact factor: 25.071

2.  In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).

Authors:  Krystyna M Kazmierczak; Masakatsu Tsuji; Mark G Wise; Meredith Hackel; Yoshinori Yamano; Roger Echols; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2018-10-26       Impact factor: 5.283

Review 3.  Stenotrophomonas, Achromobacter, and nonmelioid Burkholderia species: antimicrobial resistance and therapeutic strategies.

Authors:  Iain J Abbott; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

4.  Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.

Authors:  Marco Falcone; Giusy Tiseo; Manuela Nicastro; Alessandro Leonildi; Alessandra Vecchione; Costanza Casella; Francesco Forfori; Paolo Malacarne; Fabio Guarracino; Simona Barnini; Francesco Menichetti
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

5.  In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.

Authors:  James A Karlowsky; Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; Daniel F Sahm
Journal:  Int J Antimicrob Agents       Date:  2018-11-22       Impact factor: 5.283

Review 6.  Achromobacter respiratory infections.

Authors:  Colin E Swenson; Ruxana T Sadikot
Journal:  Ann Am Thorac Soc       Date:  2015-02

7.  Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects.

Authors:  Takayuki Katsube; Yutaka Saisho; Jingoro Shimada; Hidetoshi Furuie
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

8.  Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.

Authors:  Kenneth V I Rolston; Baghat Gerges; Samuel Shelburne; Samuel L Aitken; Issam Raad; Randall A Prince
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

9.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421

10.  In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria.

Authors:  Akinobu Ito; Takafumi Sato; Merime Ota; Miki Takemura; Toru Nishikawa; Shinsuke Toba; Naoki Kohira; Satoshi Miyagawa; Naoki Ishibashi; Shuhei Matsumoto; Rio Nakamura; Masakatsu Tsuji; Yoshinori Yamano
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191
View more
  4 in total

Review 1.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 2.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

3.  In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?

Authors:  Clémence Beauruelle; Claudie Lamoureux; Arsid Mashi; Sophie Ramel; Jean Le Bihan; Thomas Ropars; Anne Dirou; Anandadev Banerjee; Didier Tandé; Hervé Le Bars; Geneviève Héry-Arnaud
Journal:  Microorganisms       Date:  2021-11-30

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.

Authors:  Muhammad Bilal; Lobna El Tabei; Sören Büsker; Christian Krauss; Uwe Fuhr; Max Taubert
Journal:  Clin Pharmacokinet       Date:  2021-08-22       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.